Brief: Societal CDMO Selected By AmyriAD Pharma to Provide Clinical Trials Services
01/06/2022 12:51
June 1 (Reuters) - Societal CDMO Inc SCTL.O :
* SOCIETAL CDMO SELECTED BY AMYRIAD PHARMA TO PROVIDE
CLINICAL
TRIALS SERVICES TO SUPPORT PIVOTAL PHASE 3 PROGRAM FOR
ALZHEIMER’S DISEASE TREATMENT, AD101
* SOCIETAL CDMO INC - NEW CONTRACT VALUED AT NEARLY $1.0
MILLION
Source text for Eikon: ID:nGNX5l11gv
Further company coverage: SCTL.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Societal CDMO
See all newsBrief: Corerx Inc Completes Acquisition Of Societal CDMO Inc
Societal CDMO Inc reports results for the quarter ended in December - Earnings Summary
Brief: Societal CDMO Inc Received Notice From Nasdaq Stating Co Regained Compliance With Nasdaq Listing Rule 5550(A)(2) On March 14
Brief: Societal Cdmo Enters Into Definitive Agreement To Be Acquired By Corerx, Inc.
Societal CDMO Inc expected to post a loss of 1 cent a share - Earnings Preview